<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185640</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-11960</org_study_id>
    <secondary_id>78998</secondary_id>
    <secondary_id>BMT153</secondary_id>
    <nct_id>NCT00185640</nct_id>
    <nct_alias>NCT00186615</nct_alias>
  </id_info>
  <brief_title>Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure how frequently and to what degree a complication of transplant cell acute graft
      versus host disease (GvHD) occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate if TLI-ATG conditioning followed by allogeneic hematpoietic cell
      transplant (HCT), which has provided excellent overall survival for patients with relapsed
      lymphoma after failed autologous HCT, provides a similar benefit in the setting of elderly
      patients with hematologic malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Graft vs Host Disease (GvHD)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.
Skin manifestations Skin Stages
0: No rash
1: Maculopapular (MP) rash &lt;25% of body surface area
2: MP rash on 25-50% of body surface area
3: Generalized erythroderma (ED)
4: Generalized ED with bullous formation and desquamation
Liver Stages (Bilirubin in mg/dL)
0: &lt;2
1: 2-3
2: 3.01-6
3: 6.01-15.0
4: &gt;15
Gastrointestinal (GI) Stages (diarrhea)
0: None or &lt; 500 mL/day
1: 500-999 mL/day
2: 1000-1499 mL/day
3: &gt;1500 mL/day
4: Severe abdominal pain, with or without ileus
Glucksberg Overall grade
Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%.
Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80
Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60
Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Graft vs Host Disease (GvHD), All Evaluable</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.
Skin manifestations Skin Stages
0: No rash
1: Maculopapular (MP) rash &lt;25% of body surface area
2: MP rash on 25-50% of body surface area
3: Generalized erythroderma (ED)
4: Generalized ED with bullous formation and desquamation
Liver Stages (Bilirubin in mg/dL)
0: &lt;2
1: 2-3
2: 3.01-6
3: 6.01-15.0
4: &gt;15
Gastrointestinal (GI) Stages (diarrhea)
0: None or &lt; 500 mL/day
1: 500-999 mL/day
2: 1000-1499 mL/day
3: &gt;1500 mL/day
4: Severe abdominal pain, with or without ileus
Glucksberg Overall grade
Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%.
Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80
Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60
Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse</measure>
    <time_frame>3 years</time_frame>
    <description>Reports the overall rate of disease relapse, occurring any time within 3 years after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>Reports the proportion of subjects who neither died due to any cause nor experienced relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Reports the proportion of participants who expired within 1 year due to any complication or failure of the transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Blood Cancer</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Non-myeloablative transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL</description>
    <arm_group_label>Non-myeloablative transplantation</arm_group_label>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT</description>
    <arm_group_label>Non-myeloablative transplantation</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Begins on day 0 after HCT at a dose of 15 mg/kg. Patients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.</description>
    <arm_group_label>Non-myeloablative transplantation</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-Colony Stimulating Factor</intervention_name>
    <description>Received on day 0</description>
    <arm_group_label>Non-myeloablative transplantation</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>colony-stimulating factor 3</other_name>
    <other_name>csf 3</other_name>
    <other_name>G-CSF</other_name>
    <other_name>GCSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Lymphoid Irradiation</intervention_name>
    <description>0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.</description>
    <arm_group_label>Non-myeloablative transplantation</arm_group_label>
    <other_name>TLI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Any patient with one of the following hematolymphoid malignancies or syndromes in whom
             allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease
             categories include:

               -  Indolent advanced stage non-Hodgkin lymphomas

               -  Mantle cell lymphoma

               -  Chronic lymphocytic leukemia

               -  Hodgkin disease (Hodgkin's lymphoma)

               -  Acute leukemias in complete remission

               -  Aplastic anemia

               -  Paroxysmal nocturnal hemoglobinuria

               -  Myelodysplastic or myeloproliferative syndromes.

               -  Other selected malignancies/disorders may also be considered but must be approved
                  by the transplant team and the Principal Investigator.

          -  Age &gt; 50 years, or if &lt; 50 years of age, considered to be at high risk for
             regimen-related toxicity associated with conventional myeloablative transplants due to
             pre-existing medical conditions or prior therapy.

          -  A fully human leukocyte antigen (HLA)-identical sibling or matched unrelated donor is
             available. Potential participants with one antigen mismatched donors can be considered
             but only after discussion with the transplant team and the Principal Investigator.

          -  Participant must be competent to give consent.

        EXCLUSION CRITERIA:

          -  Progressive hematolymphoid malignancies despite conventional therapies, or acute
             leukemias not in complete remission.

          -  Uncontrolled central nervous system (CNS) involvement with disease

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Pregnant

          -  Cardiac ejection fraction &lt; 30%

          -  Uncontrolled cardiac failure

          -  Pulmonary diffusing capacity (DLCO) &lt; 40% predicted

          -  Elevation of bilirubin to &gt; 3 mg/dL

          -  Transaminases &gt; 4 x the upper limit of normal

          -  Creatinine clearance &lt; 50 cc/min (24-hour urine collection)

          -  Karnofsky performance score &lt; 60%

          -  Poorly controlled hypertension on multiple antihypertensives

          -  Documented fungal disease that is progressive despite treatment

          -  HIV-positive. Other viral infections, ie, Hepatitis B- and C- positive, evaluated on a
             case-by-case basis

          -  Psychiatric disorders or psychosocial problems which in the opinion of the primary
             physician or Principal Investigator would place the patient at unacceptable risk from
             this regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lowsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005 Sep 29;353(13):1321-31. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.</citation>
    <PMID>16192477</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones CD, Arai S, Lowsky R, Tyan DB, Zehnder JL, Miklos DB. Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Br J Haematol. 2010 Sep;150(5):637-9. doi: 10.1111/j.1365-2141.2010.08252.x. Epub 2010 Jun 7.</citation>
    <PMID>20528878</PMID>
  </results_reference>
  <results_reference>
    <citation>Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.</citation>
    <PMID>26146806</PMID>
  </results_reference>
  <results_reference>
    <citation>Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009 Jul 30;114(5):1099-109. doi: 10.1182/blood-2009-03-211441. Epub 2009 May 7.</citation>
    <PMID>19423725</PMID>
  </results_reference>
  <results_reference>
    <citation>Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R. Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.</citation>
    <PMID>24607552</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>December 1, 2016</results_first_submitted>
  <results_first_submitted_qc>September 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2017</results_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Robert Lowsky</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-myeloablative Transplantation</title>
          <description>Cyclosporine: 3 to 5 mg/kg twice-a-day (BID); intravenous (IV) or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; subcutaneous (SQ)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Transplanted</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>90 Days Post-transplant</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-myeloablative Transplantation</title>
          <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Biphenotypic Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Leukemia, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Monocytic Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Myeloid Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Promyelocytic Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angioimmunoblastic T-Cell Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B lymphoblastic leukemia/lymphoma, NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Cell Chr. Lymph. Leuk./Small Lymph. Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myelogenous Leukemia, Bcr/Abl Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myeloid Leukemia, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myeloproliferative Disease, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cutaneous T-Cell Lymphoma, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicular Lymphoma, Grade 1-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkin Lymphoma, Nodular Sclerosis, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkin Lymphoma, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant Lymphoma, Non-Hodgkin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mantle Cell Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal Zone B-Cell Lymphoma, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mature T-Cell Lymphoma, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ml, Large B-Cell, Diffuse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ml, Small B Lymphocytic, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic Syndrome, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precursor Cell Lymphoblastic Leukemia, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolymphocytic Leukemia, Nos</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolymphocytic Leukemia, T-Cell Type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcutaneous Panniculitis-Like T-Cell Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Graft vs Host Disease (GvHD)</title>
        <description>The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.
Skin manifestations Skin Stages
0: No rash
1: Maculopapular (MP) rash &lt;25% of body surface area
2: MP rash on 25-50% of body surface area
3: Generalized erythroderma (ED)
4: Generalized ED with bullous formation and desquamation
Liver Stages (Bilirubin in mg/dL)
0: &lt;2
1: 2-3
2: 3.01-6
3: 6.01-15.0
4: &gt;15
Gastrointestinal (GI) Stages (diarrhea)
0: None or &lt; 500 mL/day
1: 500-999 mL/day
2: 1000-1499 mL/day
3: &gt;1500 mL/day
4: Severe abdominal pain, with or without ileus
Glucksberg Overall grade
Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%.
Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80
Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60
Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40</description>
        <time_frame>100 days post-transplant</time_frame>
        <population>Reports the incidence of Grades 2 to 4 acute GvHD, as observed for the initial 37 participants treated on this study, who constitute the Primary Analysis for the study. See linked citation Lowsky, et al. NEJM. 29Sep2005;353(13)1321-1331.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-myeloablative Transplantation</title>
            <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft vs Host Disease (GvHD)</title>
          <description>The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.
Skin manifestations Skin Stages
0: No rash
1: Maculopapular (MP) rash &lt;25% of body surface area
2: MP rash on 25-50% of body surface area
3: Generalized erythroderma (ED)
4: Generalized ED with bullous formation and desquamation
Liver Stages (Bilirubin in mg/dL)
0: &lt;2
1: 2-3
2: 3.01-6
3: 6.01-15.0
4: &gt;15
Gastrointestinal (GI) Stages (diarrhea)
0: None or &lt; 500 mL/day
1: 500-999 mL/day
2: 1000-1499 mL/day
3: &gt;1500 mL/day
4: Severe abdominal pain, with or without ileus
Glucksberg Overall grade
Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%.
Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80
Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60
Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40</description>
          <population>Reports the incidence of Grades 2 to 4 acute GvHD, as observed for the initial 37 participants treated on this study, who constitute the Primary Analysis for the study. See linked citation Lowsky, et al. NEJM. 29Sep2005;353(13)1321-1331.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft vs Host Disease (GvHD), All Evaluable</title>
        <description>The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.
Skin manifestations Skin Stages
0: No rash
1: Maculopapular (MP) rash &lt;25% of body surface area
2: MP rash on 25-50% of body surface area
3: Generalized erythroderma (ED)
4: Generalized ED with bullous formation and desquamation
Liver Stages (Bilirubin in mg/dL)
0: &lt;2
1: 2-3
2: 3.01-6
3: 6.01-15.0
4: &gt;15
Gastrointestinal (GI) Stages (diarrhea)
0: None or &lt; 500 mL/day
1: 500-999 mL/day
2: 1000-1499 mL/day
3: &gt;1500 mL/day
4: Severe abdominal pain, with or without ileus
Glucksberg Overall grade
Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%.
Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80
Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60
Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40</description>
        <time_frame>100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-myeloablative Transplantation</title>
            <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft vs Host Disease (GvHD), All Evaluable</title>
          <description>The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.
Skin manifestations Skin Stages
0: No rash
1: Maculopapular (MP) rash &lt;25% of body surface area
2: MP rash on 25-50% of body surface area
3: Generalized erythroderma (ED)
4: Generalized ED with bullous formation and desquamation
Liver Stages (Bilirubin in mg/dL)
0: &lt;2
1: 2-3
2: 3.01-6
3: 6.01-15.0
4: &gt;15
Gastrointestinal (GI) Stages (diarrhea)
0: None or &lt; 500 mL/day
1: 500-999 mL/day
2: 1000-1499 mL/day
3: &gt;1500 mL/day
4: Severe abdominal pain, with or without ileus
Glucksberg Overall grade
Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%.
Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80
Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60
Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Relapse</title>
        <description>Reports the overall rate of disease relapse, occurring any time within 3 years after transplant</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-myeloablative Transplantation</title>
            <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Relapse</title>
          <description>Reports the overall rate of disease relapse, occurring any time within 3 years after transplant</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>3 and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-myeloablative Transplantation</title>
            <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival (EFS)</title>
        <description>Reports the proportion of subjects who neither died due to any cause nor experienced relapse.</description>
        <time_frame>3 and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-myeloablative Transplantation</title>
            <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS)</title>
          <description>Reports the proportion of subjects who neither died due to any cause nor experienced relapse.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-related Mortality</title>
        <description>Reports the proportion of participants who expired within 1 year due to any complication or failure of the transplant.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-myeloablative Transplantation</title>
            <description>Cyclosporine: 3 to 5 mg/kg BID; IV or oral
Thymoglobulin: 7.5 to 10 mg/kg; IV
Mycophenolate mofetil: 15 mg/kg BID or Q 8 hours
G-CSF: 16 mcg/kg; SQ</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-related Mortality</title>
          <description>Reports the proportion of participants who expired within 1 year due to any complication or failure of the transplant.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-myeloablative Transplantation</title>
          <description>Per the Common Rule, adverse events other than death, secondary malignancy, or relapse were not collected.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Deaths</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary malignancy</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Lowsky</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-0822</phone>
      <email>rlowsky@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

